Login / Signup

PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma.

Arathi MohanElit QuingalahuaValerie GunchickSimi PaulChandan Kumar-SinhaOxana CryslerMark M ZalupskiVaibhav Sahai
Published in: The oncologist (2024)
This is the first case series to describe PARPi treatment in IDH1 mutated iCCA. Results underscore the limitation of PARPi monotherapy, potentially support combined PARPi therapies, and highlight a need for effective treatment options for patients with IDH1 mutated iCCA.
Keyphrases
  • wild type
  • low grade
  • combination therapy
  • dna damage
  • dna repair
  • open label
  • high grade
  • randomized controlled trial
  • clinical trial
  • oxidative stress
  • study protocol
  • double blind